Claims
- 1. Basic amide compounds of GE 2270 and GE 2270-like antibodies of formula I ##STR40## wherein: R.sup.1 represents hydrogen, (C.sub.1 -C.sub.4)alkyl or di(C.sub.1 -C.sub.4)alkylamino(C.sub.1 -C.sub.4)alkylene, alk represents (C.sub.1 -C.sub.4)alkylene or (C.sub.2 -C.sub.5)alkylene-carbonyl,
- R.sup.2 represents a NR.sup.3 R.sup.4 group wherein
- R.sup.3 represents (C.sub.1 -C.sub.4)alkyl, hydroxy(C.sub.1 -C.sub.4)alkylene, or di(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkylene, and
- R.sup.4 represents (C.sub.1 -C.sub.4)alkyl, di(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkylene or hydroxy(C.sub.1 -C.sub.4)alkylene,
- or a five or six membered heterocycle ring having one or two nitrogen atoms, or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms or oxygen atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.4)alkyl, hydroxy(C.sub.1 -C.sub.4)alkylene, di(C.sub.1 -C.sub.4)alkylamino and di(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkylene;
- or R.sup.1 and alk-R.sup.2 together with the adjacent nitrogen atom form a five or six membered heterocycle ring having one or two nitrogen atoms or having one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.4)alkyl, di(C.sub.1 -C.sub.4)alkylamino, di(C.sub.1 -C.sub.4)alkylamino(C.sub.1 -C.sub.4)alkylene, hydroxy(C.sub.1 -C.sub.4)alkylene and a alk.sub.2 -R.sup.5 group wherein
- alk.sub.2 is (C.sub.1 -C.sub.4)alkylene and
- R.sup.5 is a NR.sup.6 R.sup.7 group wherein
- R.sup.6 represents (C.sub.1 -C.sub.4)alkyl or di(C.sub.1 -C.sub.4)alkyl-amino(C.sub.1 -C.sub.4)alkylene and
- R.sup.7 represents (C.sub.1 -C.sub.4)alkyl or di(C.sub.1 -C.sub.4)alkyl-amino(C.sub.1 -C.sub.4)alkylene
- or a five or six membered heterocycle ring having one or two nitrogen atoms, or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.4)alkyl, hydroxy(C.sub.1 -C.sub.4)alkylene, di(C.sub.1 -C.sub.4)alkylamino and di(C.sub.1 -C.sub.4)alkylamino(C.sub.1 -C.sub.4)alkylene
- and the group of formula ##STR41## represents the antibiotic core portion of the formula ##STR42## wherein: W.sup.1 represents phenyl
- W.sup.2 represents hydroxy
- or both W.sup.1 and W.sup.2 represent methyl,
- X.sup.1 represents hydrogen or methyl,
- X.sup.2 represents hydrogen, methyl or methoxymethylene,
- with the proviso that when both W.sup.1 and W.sup.2 are methyl, then X.sup.1 is methyl and X.sup.2 is hydrogen,
- or a pharmaceutical acceptable salt thereof.
- 2. Compound according to claim 1 of formula II ##STR43## wherein R.sup.1, alk, R.sup.2 and the group GE are as defined in claim 1.
- 3. Compound according to claim 1 wherein
- R.sup.1 represents hydrogen or (C.sub.1 -C.sub.4)alkyl,
- alk represents (C.sub.1 -C.sub.4)alkylene or (C.sub.2 -C.sub.5)alkylene-carbonyl,
- R.sup.2 represents a NR.sup.3 R.sup.4 group wherein
- R.sup.3 represents (C.sub.1 -C.sub.4)alkyl and
- R.sup.4 represents (C.sub.1 -C.sub.4)alkyl or di(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkylene,
- or a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom maybe optionally substituted with a group selected from (C.sub.1 -C.sub.4)alkyl and hydroxy(C.sub.1 -C.sub.4)alkylene;
- or R.sup.1 and alk-R.sup.2 together with the adjacent nitrogen atom form a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.4)alkyl, di(C.sub.1 -C.sub.4)alkylamino, di(C.sub.1 -C.sub.4)alkylamino(C.sub.1 -C.sub.4)alkylene and a alk.sub.2 -R.sup.5 group wherein
- alk.sub.2 is (C.sub.1 -C.sub.2)alkylene and
- R.sup.5 is a NR.sup.6 R.sup.7 group wherein
- R.sup.6 represents (C.sub.1 -C.sub.4)alkyl and
- R.sup.7 represents (C.sub.1 -C.sub.4)alkyl or di(C.sub.1 -C.sub.4)alkyl-amino(C.sub.1 -C.sub.4)alkylene
- or a five or six membered heterocycle ring having one or two nitrogen atoms or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms.
- 4. Compound according to claim 1 wherein
- R.sup.1 represents hydrogen or (C.sub.1 -C.sub.2)alkyl,
- alk represents (C.sub.1 -C.sub.3)alkylene or (C.sub.2 -C.sub.3)alkylene-carbonyl,
- R.sup.2 represents a NR.sup.3 R.sup.4 group wherein
- R.sup.3 represents (C.sub.1 -C.sub.3)alkyl and
- R.sup.4 represents (C.sub.1 -C.sub.3)alkyl or di(C.sub.1 -C.sub.2)alkylamino-(C.sub.1 -C.sub.2)alkylene,
- or a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl and hydroxy(C.sub.1 -C.sub.2)alkylene;
- or R.sup.1 and alk-R.sup.2 together with the adjacent nitrogen atom form a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl, di(C.sub.1 -C.sub.2)alkylamino, di(C.sub.1 -C.sub.2)alkylamino(C.sub.1 -C.sub.2)alkylene and a alk.sub.2 -R.sup.1 group wherein
- alk.sub.2 is (C.sub.1 -C.sub.2)alkylene and
- R.sup.5 is a NR.sup.6 R.sup.7 group wherein
- R.sup.6 represents (C.sub.1 -C.sub.2)alkyl and
- R.sup.7 represents (C.sub.1 -C.sub.2)alkyl or di(C.sub.1 -C.sub.2)alkyl-amino(C.sub.1 -C.sub.2)alkylene
- or a five or six membered heterocycle ring having one or two nitrogen atoms or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms.
- 5. Compound according to claim 1 wherein the group GE is such that W.sup.1 is phenyl, W.sup.2 is hydroxy, X.sup.1 is methyl, X.sup.2 is methoxymethylene and
- R.sup.1 represents hydrogen or (C.sub.1 -C.sub.2)alkyl,
- alk represents (C.sub.1 -C.sub.3)alkylene,
- R.sup.2 represents a NR.sup.3 R.sup.4 group wherein
- R.sup.3 represents (C.sub.1 -C.sub.3)alkyl and
- R.sup.4 represents (C.sub.1 -C.sub.3)alkyl or di(C.sub.1 -C.sub.2 alkylamino-(C.sub.1 -C.sub.2)alkylene,
- or a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl and hydroxy(C.sub.1 -C.sub.2)alkylene;
- or R.sup.1 and alk-R.sup.2 together with the adjacent nitrogen atom form a five or six membered heterocycle ring having one or two nitrogen atoms with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl, di(C.sub.1 -C.sub.2)alkylamino, di(C.sub.1 -C.sub.2)alkylamino(C.sub.1 -C.sub.2)alkylene and a alk.sub.2 -R.sup.5 group wherein
- alk.sub.2 is (C.sub.1 -C.sub.2)alkylene and
- R.sup.5 is a NR.sup.6 R.sup.7 group wherein
- R.sup.6 represents (C.sub.1 -C.sub.2)alkyl and
- R.sup.7 represents (C.sub.1 -C.sub.2)alkyl or di(C.sub.1 -C.sub.2)alkyl-amino(C.sub.1 -C.sub.2)alkylene
- or a five or six membered heterocycle ring having one or two nitrogen atoms or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms.
- 6. Compound according to claim 2 wherein
- R.sup.1 represents hydrogen or (C.sub.1 -C.sub.4)alkyl,
- alk represents (C.sub.1 -C.sub.4)alkylene or (C.sub.2 -C.sub.5)alkylene-carbonyl,
- R.sup.2 represents a NR.sup.3 R.sup.4 group wherein
- R.sup.3 represents (C.sub.1 -C.sub.4)alkyl and
- R.sup.4 represents (C.sub.1 -C.sub.4)alkyl or di(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkylene,
- or a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.4)alkyl and hydroxy(C.sub.1 -C.sub.4)alkylene;
- or R.sup.1 and alk-R.sup.2 together with the adjacent nitrogen atom form a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.4)alkyl, di(C.sub.1 -C.sub.4)alkylamino, di((C.sub.1 -C.sub.4)alkylamino(C.sub.1 -C.sub.4)alkylene and a alk.sub.2 -R.sup.5 group wherein
- alk.sub.2 is (C.sub.1 -C.sub.4)alkylene and
- R.sup.5 is a NR.sup.6 R.sup.7 group wherein
- R.sup.6 represents (C.sub.1 -C.sub.4)alkyl and
- R.sup.7 represents (C.sub.1 -C.sub.4)alkyl or di(C.sub.1 -C.sub.4)alkyl-amino(C.sub.1 -C.sub.4)alkylene
- or a five or six membered heterocycle ring having one or two nitrogen atoms or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms.
- 7. Compound according to claim 2 wherein
- R.sup.1 represents hydrogen or (C.sub.1 -C.sub.2)alkyl,
- alk represents (C.sub.1 -C.sub.3)alkylene or (C.sub.2 -C.sub.3)alkylene-carbonyl,
- R.sup.2 represents a NR.sup.3 R.sup.4 group wherein
- R.sup.3 represents (C.sub.1 -C.sub.3)alkyl and
- R.sup.4 represents (C.sub.1 -C.sub.3)alkyl or di(C.sub.1 -C.sub.2)alkylamino-(C.sub.1 -C.sub.2)alkylene,
- or a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl and hydroxy(C.sub.1 -C.sub.2)alkylene;
- or R.sup.1 and alk-R.sup.2 together with the adjacent nitrogen atom form a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl, di(C.sub.1 -C.sub.2)alkylamino, di(C.sub.1 -C.sub.2)alkylamino(C.sub.1 -C.sub.2)alkylene and a alk.sub.2 -R.sup.5 group wherein
- alk.sub.2 is (C.sub.1 -C.sub.2)alkylene and
- R.sup.5 is a NR.sup.6 R.sup.7 group wherein
- R.sup.6 represents (C.sub.1 -C.sub.2)alkyl and
- R.sup.7 represents (C.sub.1 -C.sub.2)alkyl or di(C.sub.1 -C.sub.2)alkyl-amino(C.sub.1 -C.sub.2)alkylene
- or a five or six membered heterocycle ring having one or two nitrogen atoms or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms.
- 8. Compound according to claim 2 wherein the group GE is such that W.sup.1 is phenyl, W.sup.2 is hydroxy, X.sup.1 is methyl, X.sup.2 is methoxymethylene and
- R.sup.1 represents hydrogen or (C.sub.1 -C.sub.2)alkyl,
- alk represents (C.sub.1 -C.sub.3)alkylene,
- R.sup.2 represents a NR.sup.3 R.sup.4 group wherein
- R.sup.3 represents (C.sub.1 -C.sub.3)alkyl and
- R.sup.4 represents (C.sub.1 -C.sub.3)alkyl or di(C.sub.1 -C.sub.2)alkylamino-(C.sub.1 -C.sub.2)alkylene,
- or a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl and hydroxy(C.sub.1 -C.sub.2)alkylene;
- or R.sup.1 and alk-R.sup.2 together with the adjacent nitrogen atom form a five or six membered heterocycle ring having one or two nitrogen atoms, with the remaining atoms of the heterocycle ring being carbon atoms, wherein any nitrogen atom or any carbon atom may be optionally substituted with a group selected from (C.sub.1 -C.sub.2)alkyl, di(C.sub.1 -C.sub.2)alkylamino, di(C.sub.1 -C.sub.2)alkylamino(C.sub.1 -C.sub.2)alkylene and a alk.sub.2 -R.sup.5 group wherein
- alk.sub.2 is (C.sub.1 -C.sub.2)alkylene and
- R.sup.5 is a NR.sup.6 R.sup.7 group wherein
- R.sup.6 represents (C.sub.1 -C.sub.2)alkyl and
- R.sup.7 represents (C.sub.1 -C.sub.2)alkyl or di(C.sub.1 -C.sub.2)alkyl-amino(C.sub.1 -C.sub.2)alkylene
- or a five or six membered heterocycle ring having one or two nitrogen atoms or one nitrogen atom and one oxygen atom, with the remaining atoms of the heterocycle ring being carbon atoms.
- 9. A compound according to claim 1 which is ##STR44##10.
- 10. A compound according to claim 1 which is
- 11. A compound according to claim 1 which is
- 12. A compound according to claim 1 which is
- 13. A compound according to claim 1 which is
- 14. A compound according to claim 1 which is
- 15. A compound according to claim 1 which is
- 16. A compound according to claim 1 which is
- 17. A compound according to claim 1 which is
- 18. A compound according to claim 1 which is
- 19. A compound according to claim 1 which is
- 20. A compound according to claim 1 which is
- 21. A compound according to claim 1 which is
- 22. A compound according to claim 1 which is
- 23. A compound according to claim 1 which is
- 24. A compound according to claim 1 which is
- 25. A compound according to claim 1 which is
- 26. A compound according to claim 1 which is
- 27. A compound according to claim 1 which is
- 28. A compound according to claim 1 which is
- 29. A compound according to claim 1 which is
- 30. Compound of formula wherein Z' represents (C.sub.1 -C.sub.4)alkyl and GE is as defined in claim 1.
- 31. Process for preparing a compound of claim 1 which comprises:
- a) reacting a compound of formula III ##STR45## wherein the group GE is as defined in formula I, with a serinamide, or an acid addition salt thereof, of formula IV: ##STR46## wherein R.sup.1, alk and R.sup.2 are as in claim 1, in an inert aprotic organic solvent in the presence of a condensing agent;
- b) cyclizing the serine moiety of the obtained compound of formula IlIa ##STR47## with a suitable cyclizing reactant, in order to obtain the desired compound of formula I.
- 32. Process for preparing a compound of claim 1 which comprises reacting a compound of formula V ##STR48## wherein the group GE is as defined in claim 1, with a serinamide, or an acid addition salt thereof, of formula IV: ##STR49## wherein R.sup.1, alk and R.sup.2 are as in claim 1, in a protic organic solvent.
- 33. Process for preparing a compound of claim 1 which comprises reacting a compound of formula VI ##STR50## or a base addition salt thereof, wherein the group GE is as defined in formula I, with an amine, or an acid addition salt thereof, of formula IVa: ##STR51## wherein R.sup.1, alk, and R.sup.2 are as defined in formula I, in the presence of an inert organic solvent and of a condensing agent.
- 34. Pharmaceutical composition containing a compound of claim 1 in admixture with a pharmaceutically acceptable carrier.
- 35. Pharmaceutical composition containing a compound of claim 2 in admixture with a pharmaceutically acceptable carrier.
- 36. Pharmaceutical composition containing a compound of claim 3 in admixture with a pharmaceutically acceptable carrier.
- 37. Pharmaceutical composition containing a compound of claim 4 in admixture with a pharmaceutically acceptable carrier.
- 38. Pharmaceutical composition containing a compound of claim 5 in admixture with a pharmaceutically acceptable carrier.
- 39. Method for the treatment of bacterial infections comprising administering an effective amount of a compound of claim 1 to a patient in need thereof.
- 40. Method for the treatment of bacterial infections comprising administering an effective amount of a compound of claim 2 to a patient in need thereof.
- 41. Method for the treatment of bacterial infections comprising administering an effective amount of a compound of claim 3 to a patient in need thereof.
- 42. Method for the treatment of bacterial infections comprising administering an effective amount of a compound of claim 4 to a patient in need thereof.
- 43. Method for the treatment of bacterial infections comprising administering an effective amount of a compound of claim 5 to a patient in need thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
95101597 |
Feb 1995 |
EPX |
|
Parent Case Info
The present application is a 371 of PCT/EP96/00407, filed Feb. 1, 1996.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP96/00407 |
2/1/1996 |
|
|
7/31/1997 |
7/31/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/24607 |
8/15/1996 |
|
|
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
5139778 |
Selva et al. |
Aug 1992 |
|
5202241 |
Selva et al. |
Apr 1993 |
|
5514649 |
Selva et al. |
May 1996 |
|
5599791 |
Tavecchia et al. |
Feb 1997 |
|
5891869 |
Lociuro et al. |
Apr 1999 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
451 486 |
Oct 1991 |
EPX |
0 494 078 A1 |
Jul 1992 |
EPX |
529410 |
Mar 1993 |
EPX |
WO 9212172 |
Jul 1992 |
WOX |
WO 9624607 |
Aug 1996 |
WOX |
WO 9730078 |
Aug 1997 |
WOX |
Non-Patent Literature Citations (1)
Entry |
"Novel Antibiotics, Amythiamicins III. Structure Elucidations of Amythiamicins A, B and C" The Journal of Antibiotics, vol. 47, No. 10, pp. 1153-1159, (1994). |